Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TricValve System in Severe Tricuspid Regurgitation
NCT06458907Not yet recruiting
- Sponsor
- P+F Products + Features
- Start
- Oct 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in tricuspid regurgitation and Caval reflux (3 arms), sponsored by P+F Products + Features. Primary endpoints: Caval Reflux grade reduction at 6 months, Hierarchical composite endpoint including KCCQ, NYHA, and 6MWT at 6 months and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
tricuspid regurgitationCaval reflux
Beyond the preview
Go deeper on NCT06458907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06458907.